Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Oversight and Government Reform, Natural Resources, Agriculture, and Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Update drug scheduling rules to match current medical science and research needs.
The problem
Current drug scheduling system hasn't kept pace with modern medical knowledge. Rules may prevent legitimate research and don't reflect how drugs actually work medically.
The proposal
Change how drugs are classified under controlled substances law. Create new scheduling system. Give different agencies new powers. Allow more scientific research on controlled substances.
The impact
Researchers, patients, doctors, and pharmaceutical companies affected. May expand medical research options and drug development. Could change drug regulations and enforcement.
Updating rules could allow scientists to study medicines that are currently blocked. This might lead to new treatments for diseases. Research institutions and patients seeking new therapies could benefit.
Aligning law with medical facts means regulations match what doctors actually know works. This prevents outdated rules from blocking helpful medicines. Drug classification would be more accurate.
Clarifying which agencies control what prevents confusion and gaps in responsibility. Different departments know exactly what they must do. Government coordination improves.
Easier research rules could help companies develop new medicines faster. This may create jobs in drug development. Economy gains from innovation in healthcare sector.
Relaxing scheduling rules could increase drug abuse if not carefully managed. Dangerous substances might become more accessible. Public safety concerns arise with looser restrictions.
New systems are complex and take time to implement correctly. Police and agencies must retrain on new rules. Mistakes during transition could cause problems.
The bill summary is not available, so the exact changes are unknown. Hidden provisions could have unintended consequences. Voters cannot see what Congress actually plans to do.
If rescheduling is too loose, pharmaceutical companies might push drugs with addiction risks. Profit motives could override safety. Patients vulnerable to new drug problems.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
No donor data found for current cycle
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
No lobbying disclosures matched this bill.